Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app ease suffering for advanced cancer patients?

NCT ID NCT04989556

Symptom relief Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a technology-enhanced symptom monitoring program, used alongside standard in-person and remote palliative care, can improve quality of life for 119 adults with advanced solid tumors who are also in phase I immunotherapy trials. Participants use the program to report symptoms, and researchers track changes in distress and satisfaction. The goal is to see if adding digital tools makes palliative care more effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
technology-enhanced symptom monitoring program
What this could lead to
If it works, this could show that adding a digital symptom tracker to standard palliative care improves quality of life for people with advanced cancer.
What could go wrong
This is a small, early-stage study with only 119 participants, so results may not apply to everyone. The intervention is supportive, not curative, so it won't change the cancer itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

119 people

The number who actually took part.

Started

Aug 2020

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * PATIENT: Diagnosis of advanced solid tumor * PATIENT: Oncologic plan for a phase I trial * PATIENT: High symptom burden (defined as a score of \>= 4 on at least 1 Edmonton Symptom Assessment Scale \[ESAS\] symptom, AND a global distress score \[GDS\] of \>= 20) * PATIENT: Reliable telephone and internet access * PATIENT: Able to communicate verbally in English and provide informed consent * CAREGIVER: Able to communicate verbally in English and provide informed consent * CAREGIVER: Reliable telephone and internet access Exclusion Criteria: * PATIENT: Low symptom burden defined as scores \< 4 on all ESAS symptoms OR GDS \< 20 * PATIENT: Delirium (i.e. Memorial Delirium Assessment Scale \> 8) * PATIENT: No reliable telephone or internet access * CAREGIVER: Refusal to participate in this study * CAREGIVER: No reliable telephone or internet access

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced malignant solid neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced malignant solid neoplasm

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.